Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of DA-302168S in Healthy Subjects
NCT06534320Phase 1Completed
- Sponsor
- Chengdu Diao Pharmaceutical Group
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing DA-302168S with Placebo (2 arms). Primary endpoint: Safety and Tolerability at Day 9. Started Apr 2024; status: completed.
02
Drugs
DA-302168S
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06534320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534320.